FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
Subscribe To Our Newsletter & Stay Updated